摘要
目的观察肝动脉化疗栓塞(TACE)联合仑伐替尼靶向治疗中晚期肝细胞癌的临床效果。方法将2019年3月至2020年8月宝鸡市中心医院肿瘤内科及安庆市第一人民医院血液肿瘤科收治的52例中晚期肝细胞癌患者根据治疗方式分为对照组和观察组,每组26例。对照组给予TACE治疗,观察组在对照组基础上给予仑伐替尼靶向治疗。比较两组的临床疗效、肿瘤血管因子及肿瘤标志物水平、肝功能指标、毒副反应发生情况。结果观察组的疾病控制率(DCR)高于对照组,差异具有统计学意义(P<0.05);两组的客观缓解率(ORR)比较,差异无统计学意义(P>0.05)。治疗前,两组的血管内皮生长因子受体-2(VEGFR-2)、甲胎蛋白(AFP)、高尔基体糖蛋白73(GP73)水平比较,差异无统计学意义(P>0.05);治疗后,两组的VEGFR-2、AFP、GP73水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗前,两组的谷丙转氨酶(ALT)、谷草转氨酶(AST)、乳酸脱氢酶(LDH)水平比较,差异无统计学意义(P>0.05);治疗后,两组的ALT、AST、LDH水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。两组的高血压、肾功能不全、胃肠道反应、肝脏毒性、手足综合征、疲劳总发生率比较,差异均无统计学意义(P>0.05)。结论 TACE联合仑伐替尼靶向治疗中晚期肝细胞癌可控制疾病进展,降低肿瘤血管因子及肿瘤标志物水平,稳定患者的肝功能,值得临床应用和推广。
Objective To observe the clinical effect of transcatheter arterial chemoembolization(TACE) combined with lenvatinib in the targeted treatment of intermediate-advanced hepatocellular carcinoma.Methods Fifty-two patients with intermediate-advanced hepatocellular carcinoma treated in the internal medicine-oncology department of Baoji central hospital and the hematology oncology department of Anqing first people’s hospital from March 2019 to August2020 were divided into control group and observation group according to the treatment methods,with 26 cases in each group.The control group was given TACE treatment,and the observation group was given lenvatinib targeted treatment on the basis of the control group.The clinical efficacy,levels of tumor vascular factors,tumor markers,liver function indexes and occurrence of toxic and side effects were compared between the two groups.Results The disease control rate(DCR)of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05);there was no significant difference in the objective remission rate(ORR) between the two groups(P >0.05).Before treatment,there were no statistically significant differences in the levels of vascular endothelial growth factor receptor-2(VEGFR-2),alpha fetoprotein(AFP) and golgi glycoprotein 73(GP73) between the two groups(P>0.05);after treatment,the levels of VEGFR-2,AFP and GP73 in the two groups decreased,those in the observation group were lower than the control group,and the differences were statistically significant(P <0.05).Before treatment,there were no significant differences in the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST) and lactate dehydrogenase(LDH) between the two groups(P>0.05);after treatment,the levels of ALT,AST and LDH in the two groups decreased,those in the observation group were lower than the control group,and the differences were statistically significant(P<0.05).There were no significant differences in the total incidences of hypertension,renal insufficiency,gastrointestinal reaction,hepatotoxicity,hand foot syndrome and fatigue between the two groups(P >0.05).Conclusion TACE combined with lenvatinib in the total targeted treatment of intermediate-advanced hepatocellular carcinoma can control the disease progression,reduce the levels of tumor vascular factors and tumor markers,and stabilize the liver function of patients,which is worthy of clinical application and promotion.
作者
董龙科
江昊
DONG Longke;JIANG Hao(Baoji Central Hospital,Baoji 721008;Anqing First People's Hospital,Anqing 246003,China)
出处
《临床医学研究与实践》
2022年第1期42-45,共4页
Clinical Research and Practice
关键词
中晚期肝细胞癌
肝动脉化疗栓塞
仑伐替尼
intermediate-advanced hepatocellular carcinoma
transarterial chemoembolizatio
lenvatinib
